Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,261.20
(
-0.34%
)
Dow Jones
49,526.17
(
0.00%
)
Brent Oil
106.20
(
-1.18%
)
Bitcoin
77,255.88
(
-0.22%
)
News Focus
News Focus
Post# of 3757
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Tuesday, 11/06/2007 4:44:32 PM

Tuesday, November 06, 2007 4:44:32 PM

Post# of 3757
IDX-899 in vitro data shows that it does not generate cross-resistance to Sustiva. Hence, IDX-899 could theoretically be given earlier in HIV treatment than Sustiva (or Atripla) is given. (Source: Today’s CC)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote